earnings
confidence high
sentiment positive
materiality 0.75
Carlsmed Q4 revenue $15.2M (+61% YoY); FY rev $50.5M (+86%); guides FY2026 $70-75M
CARLSMED, INC.
2025-FY EPS reported
-$2.12
revenue$50,511,000
- Q4 rev $15.2M (+61% YoY), FY rev $50.5M (+86% YoY). Gross margin 76.5% Q4, 75.3% FY.
- Net loss Q4 ($8.6M), FY ($29.6M); adj. EBITDA loss Q4 ($8.4M), FY ($28.4M).
- Cash, cash equivalents, restricted cash, and ST investments $109.9M at Dec 31, 2025.
- FY2026 revenue guidance $70-75M, representing ~44% growth at midpoint over 2025.
- 2-year data showed 74% reduction in revision rates for aprevo® lumbar vs non-aprevo.